ASCT Vs CART for Patients with Relapsed LBCL in PR: Role of TMTV
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission.
Shadman M, Ahn K, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M Blood Cancer J. 2024; 14(1):108.
PMID: 38977682 PMC: 11231252. DOI: 10.1038/s41408-024-01084-w.
Alderuccio J, Reis I, Hamadani M, Nachiappan M, Leslom S, Kahl B Clin Cancer Res. 2023; 30(1):139-149.
PMID: 37855688 PMC: 10872617. DOI: 10.1158/1078-0432.CCR-23-1561.
References
1.
Dean E, Mhaskar R, Lu H, Mousa M, Krivenko G, Lazaryan A
. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020; 4(14):3268-3276.
PMC: 7391155.
DOI: 10.1182/bloodadvances.2020001900.
View
2.
Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J
. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852.
DOI: 10.1016/S0140-6736(20)31366-0.
View
3.
Wudhikarn K, Tomas A, Flynn J, Devlin S, Brower J, Bachanova V
. Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood Adv. 2022; 7(13):3192-3198.
PMC: 10338201.
DOI: 10.1182/bloodadvances.2022008294.
View
4.
Jain M, Zhao H, Wang X, Atkins R, Menges M, Reid K
. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021; 137(19):2621-2633.
PMC: 8120145.
DOI: 10.1182/blood.2020007445.
View
5.
Cheson B, Fisher R, Barrington S, Cavalli F, Schwartz L, Zucca E
. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-68.
PMC: 4979083.
DOI: 10.1200/JCO.2013.54.8800.
View